Efficacy of Olmesartan/Amlodipine Single‐Pill Combination on 24‐h Mean Systolic Blood Pressure Measured by Ambulatory Monitoring in Non‐Responders to Valsartan or Candesartan Monotherapy
ABSTRACT The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single‐pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in non‐responders to valsartan or candesartan monotherapy. Isolated systolic hypertension (ISH) is the most prevalent...
Saved in:
| Published in | The journal of clinical hypertension (Greenwich, Conn.) Vol. 27; no. 1; pp. e14929 - n/a |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
John Wiley & Sons, Inc
01.01.2025
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1524-6175 1751-7176 1751-7176 |
| DOI | 10.1111/jch.14929 |
Cover
| Abstract | ABSTRACT
The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single‐pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in non‐responders to valsartan or candesartan monotherapy. Isolated systolic hypertension (ISH) is the most prevalent form of hypertension in middle‐aged and elderly individuals. Patients aged over 55 years who did not achieve the target systolic blood pressure (SBP < 140 mmHg) with valsartan 80 mg or candesartan 8 mg for at least 4 weeks were included. Doses were escalated from 20/5 mg to 40/5 mg and finally to 40/10 mg of OLM/AML SPC until patients reached the target SBP. Efficacy was assessed via ABPM by comparing baseline values with those in the 12th week. Office blood pressure (OBP) and brachial‐ankle pulse wave velocity (baPWV) were assessed at baseline, weeks 4, 8, and 12. Fifty‐four patients (average age 64 ± 6 years; 33 males) participated. The 24‐h mean BPs decreased significantly from an average of 146.2 ± 12.7/93.3 ± 9.2 mmHg to 129.7 ± 14.3/83.4 ± 10.7 mmHg (p < 0.001), and pulse pressures (PPs) from ABPM were reduced (p < 0.001). Additionally, significant reductions in night‐time SBP standard deviations (SDs) (14.7 ± 4.7 vs. 12.5 ± 3.9, p = 0.029) were observed at 12 weeks compared to baseline. OBPs significantly dropped from 151.1 ± 9.7/89.3 ± 8.3 mmHg to 125.5 ± 13.8/77.8 ± 8.8 mmHg after 12 weeks of SPC therapy (p < 0.001). Reductions in PPs of OBP and baPWVs were also observed. OLM/AML SPC therapy effectively reduced the 24‐h mean BP, as measured by ABPM, in hypertensive patients over 55 years old who failed to achieve a target SBP (< 140 mmHg) with angiotensin receptor blocker (ARB) monotherapy using valsartan 80 mg or candesartan 8 mg.
Trial Registration: ClinicalTrials.gov identifier: NCT01713920 |
|---|---|
| AbstractList | ABSTRACT The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single‐pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in non‐responders to valsartan or candesartan monotherapy. Isolated systolic hypertension (ISH) is the most prevalent form of hypertension in middle‐aged and elderly individuals. Patients aged over 55 years who did not achieve the target systolic blood pressure (SBP < 140 mmHg) with valsartan 80 mg or candesartan 8 mg for at least 4 weeks were included. Doses were escalated from 20/5 mg to 40/5 mg and finally to 40/10 mg of OLM/AML SPC until patients reached the target SBP. Efficacy was assessed via ABPM by comparing baseline values with those in the 12th week. Office blood pressure (OBP) and brachial‐ankle pulse wave velocity (baPWV) were assessed at baseline, weeks 4, 8, and 12. Fifty‐four patients (average age 64 ± 6 years; 33 males) participated. The 24‐h mean BPs decreased significantly from an average of 146.2 ± 12.7/93.3 ± 9.2 mmHg to 129.7 ± 14.3/83.4 ± 10.7 mmHg (p < 0.001), and pulse pressures (PPs) from ABPM were reduced (p < 0.001). Additionally, significant reductions in night‐time SBP standard deviations (SDs) (14.7 ± 4.7 vs. 12.5 ± 3.9, p = 0.029) were observed at 12 weeks compared to baseline. OBPs significantly dropped from 151.1 ± 9.7/89.3 ± 8.3 mmHg to 125.5 ± 13.8/77.8 ± 8.8 mmHg after 12 weeks of SPC therapy (p < 0.001). Reductions in PPs of OBP and baPWVs were also observed. OLM/AML SPC therapy effectively reduced the 24‐h mean BP, as measured by ABPM, in hypertensive patients over 55 years old who failed to achieve a target SBP (< 140 mmHg) with angiotensin receptor blocker (ARB) monotherapy using valsartan 80 mg or candesartan 8 mg. Trial Registration: ClinicalTrials.gov identifier: NCT01713920 ABSTRACT The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single‐pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in non‐responders to valsartan or candesartan monotherapy. Isolated systolic hypertension (ISH) is the most prevalent form of hypertension in middle‐aged and elderly individuals. Patients aged over 55 years who did not achieve the target systolic blood pressure (SBP < 140 mmHg) with valsartan 80 mg or candesartan 8 mg for at least 4 weeks were included. Doses were escalated from 20/5 mg to 40/5 mg and finally to 40/10 mg of OLM/AML SPC until patients reached the target SBP. Efficacy was assessed via ABPM by comparing baseline values with those in the 12th week. Office blood pressure (OBP) and brachial‐ankle pulse wave velocity (baPWV) were assessed at baseline, weeks 4, 8, and 12. Fifty‐four patients (average age 64 ± 6 years; 33 males) participated. The 24‐h mean BPs decreased significantly from an average of 146.2 ± 12.7/93.3 ± 9.2 mmHg to 129.7 ± 14.3/83.4 ± 10.7 mmHg (p < 0.001), and pulse pressures (PPs) from ABPM were reduced (p < 0.001). Additionally, significant reductions in night‐time SBP standard deviations (SDs) (14.7 ± 4.7 vs. 12.5 ± 3.9, p = 0.029) were observed at 12 weeks compared to baseline. OBPs significantly dropped from 151.1 ± 9.7/89.3 ± 8.3 mmHg to 125.5 ± 13.8/77.8 ± 8.8 mmHg after 12 weeks of SPC therapy (p < 0.001). Reductions in PPs of OBP and baPWVs were also observed. OLM/AML SPC therapy effectively reduced the 24‐h mean BP, as measured by ABPM, in hypertensive patients over 55 years old who failed to achieve a target SBP (< 140 mmHg) with angiotensin receptor blocker (ARB) monotherapy using valsartan 80 mg or candesartan 8 mg. Trial Registration: ClinicalTrials.gov identifier: NCT01713920 The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single‐pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in non‐responders to valsartan or candesartan monotherapy. Isolated systolic hypertension (ISH) is the most prevalent form of hypertension in middle‐aged and elderly individuals. Patients aged over 55 years who did not achieve the target systolic blood pressure (SBP < 140 mmHg) with valsartan 80 mg or candesartan 8 mg for at least 4 weeks were included. Doses were escalated from 20/5 mg to 40/5 mg and finally to 40/10 mg of OLM/AML SPC until patients reached the target SBP. Efficacy was assessed via ABPM by comparing baseline values with those in the 12th week. Office blood pressure (OBP) and brachial‐ankle pulse wave velocity (baPWV) were assessed at baseline, weeks 4, 8, and 12. Fifty‐four patients (average age 64 ± 6 years; 33 males) participated. The 24‐h mean BPs decreased significantly from an average of 146.2 ± 12.7/93.3 ± 9.2 mmHg to 129.7 ± 14.3/83.4 ± 10.7 mmHg (p < 0.001), and pulse pressures (PPs) from ABPM were reduced (p < 0.001). Additionally, significant reductions in night‐time SBP standard deviations (SDs) (14.7 ± 4.7 vs. 12.5 ± 3.9, p = 0.029) were observed at 12 weeks compared to baseline. OBPs significantly dropped from 151.1 ± 9.7/89.3 ± 8.3 mmHg to 125.5 ± 13.8/77.8 ± 8.8 mmHg after 12 weeks of SPC therapy (p < 0.001). Reductions in PPs of OBP and baPWVs were also observed. OLM/AML SPC therapy effectively reduced the 24‐h mean BP, as measured by ABPM, in hypertensive patients over 55 years old who failed to achieve a target SBP (< 140 mmHg) with angiotensin receptor blocker (ARB) monotherapy using valsartan 80 mg or candesartan 8 mg. Trial Registration: ClinicalTrials.gov identifier: NCT01713920 The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single-pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in non-responders to valsartan or candesartan monotherapy. Isolated systolic hypertension (ISH) is the most prevalent form of hypertension in middle-aged and elderly individuals. Patients aged over 55 years who did not achieve the target systolic blood pressure (SBP < 140 mmHg) with valsartan 80 mg or candesartan 8 mg for at least 4 weeks were included. Doses were escalated from 20/5 mg to 40/5 mg and finally to 40/10 mg of OLM/AML SPC until patients reached the target SBP. Efficacy was assessed via ABPM by comparing baseline values with those in the 12th week. Office blood pressure (OBP) and brachial-ankle pulse wave velocity (baPWV) were assessed at baseline, weeks 4, 8, and 12. Fifty-four patients (average age 64 ± 6 years; 33 males) participated. The 24-h mean BPs decreased significantly from an average of 146.2 ± 12.7/93.3 ± 9.2 mmHg to 129.7 ± 14.3/83.4 ± 10.7 mmHg (p < 0.001), and pulse pressures (PPs) from ABPM were reduced (p < 0.001). Additionally, significant reductions in night-time SBP standard deviations (SDs) (14.7 ± 4.7 vs. 12.5 ± 3.9, p = 0.029) were observed at 12 weeks compared to baseline. OBPs significantly dropped from 151.1 ± 9.7/89.3 ± 8.3 mmHg to 125.5 ± 13.8/77.8 ± 8.8 mmHg after 12 weeks of SPC therapy (p < 0.001). Reductions in PPs of OBP and baPWVs were also observed. OLM/AML SPC therapy effectively reduced the 24-h mean BP, as measured by ABPM, in hypertensive patients over 55 years old who failed to achieve a target SBP (< 140 mmHg) with angiotensin receptor blocker (ARB) monotherapy using valsartan 80 mg or candesartan 8 mg. Trial Registration: ClinicalTrials.gov identifier: NCT01713920. The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single-pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in non-responders to valsartan or candesartan monotherapy. Isolated systolic hypertension (ISH) is the most prevalent form of hypertension in middle-aged and elderly individuals. Patients aged over 55 years who did not achieve the target systolic blood pressure (SBP < 140 mmHg) with valsartan 80 mg or candesartan 8 mg for at least 4 weeks were included. Doses were escalated from 20/5 mg to 40/5 mg and finally to 40/10 mg of OLM/AML SPC until patients reached the target SBP. Efficacy was assessed via ABPM by comparing baseline values with those in the 12th week. Office blood pressure (OBP) and brachial-ankle pulse wave velocity (baPWV) were assessed at baseline, weeks 4, 8, and 12. Fifty-four patients (average age 64 ± 6 years; 33 males) participated. The 24-h mean BPs decreased significantly from an average of 146.2 ± 12.7/93.3 ± 9.2 mmHg to 129.7 ± 14.3/83.4 ± 10.7 mmHg (p < 0.001), and pulse pressures (PPs) from ABPM were reduced (p < 0.001). Additionally, significant reductions in night-time SBP standard deviations (SDs) (14.7 ± 4.7 vs. 12.5 ± 3.9, p = 0.029) were observed at 12 weeks compared to baseline. OBPs significantly dropped from 151.1 ± 9.7/89.3 ± 8.3 mmHg to 125.5 ± 13.8/77.8 ± 8.8 mmHg after 12 weeks of SPC therapy (p < 0.001). Reductions in PPs of OBP and baPWVs were also observed. OLM/AML SPC therapy effectively reduced the 24-h mean BP, as measured by ABPM, in hypertensive patients over 55 years old who failed to achieve a target SBP (< 140 mmHg) with angiotensin receptor blocker (ARB) monotherapy using valsartan 80 mg or candesartan 8 mg. Trial Registration: ClinicalTrials.gov identifier: NCT01713920.The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single-pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in non-responders to valsartan or candesartan monotherapy. Isolated systolic hypertension (ISH) is the most prevalent form of hypertension in middle-aged and elderly individuals. Patients aged over 55 years who did not achieve the target systolic blood pressure (SBP < 140 mmHg) with valsartan 80 mg or candesartan 8 mg for at least 4 weeks were included. Doses were escalated from 20/5 mg to 40/5 mg and finally to 40/10 mg of OLM/AML SPC until patients reached the target SBP. Efficacy was assessed via ABPM by comparing baseline values with those in the 12th week. Office blood pressure (OBP) and brachial-ankle pulse wave velocity (baPWV) were assessed at baseline, weeks 4, 8, and 12. Fifty-four patients (average age 64 ± 6 years; 33 males) participated. The 24-h mean BPs decreased significantly from an average of 146.2 ± 12.7/93.3 ± 9.2 mmHg to 129.7 ± 14.3/83.4 ± 10.7 mmHg (p < 0.001), and pulse pressures (PPs) from ABPM were reduced (p < 0.001). Additionally, significant reductions in night-time SBP standard deviations (SDs) (14.7 ± 4.7 vs. 12.5 ± 3.9, p = 0.029) were observed at 12 weeks compared to baseline. OBPs significantly dropped from 151.1 ± 9.7/89.3 ± 8.3 mmHg to 125.5 ± 13.8/77.8 ± 8.8 mmHg after 12 weeks of SPC therapy (p < 0.001). Reductions in PPs of OBP and baPWVs were also observed. OLM/AML SPC therapy effectively reduced the 24-h mean BP, as measured by ABPM, in hypertensive patients over 55 years old who failed to achieve a target SBP (< 140 mmHg) with angiotensin receptor blocker (ARB) monotherapy using valsartan 80 mg or candesartan 8 mg. Trial Registration: ClinicalTrials.gov identifier: NCT01713920. ABSTRACT The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single‐pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in non‐responders to valsartan or candesartan monotherapy. Isolated systolic hypertension (ISH) is the most prevalent form of hypertension in middle‐aged and elderly individuals. Patients aged over 55 years who did not achieve the target systolic blood pressure (SBP < 140 mmHg) with valsartan 80 mg or candesartan 8 mg for at least 4 weeks were included. Doses were escalated from 20/5 mg to 40/5 mg and finally to 40/10 mg of OLM/AML SPC until patients reached the target SBP. Efficacy was assessed via ABPM by comparing baseline values with those in the 12th week. Office blood pressure (OBP) and brachial‐ankle pulse wave velocity (baPWV) were assessed at baseline, weeks 4, 8, and 12. Fifty‐four patients (average age 64 ± 6 years; 33 males) participated. The 24‐h mean BPs decreased significantly from an average of 146.2 ± 12.7/93.3 ± 9.2 mmHg to 129.7 ± 14.3/83.4 ± 10.7 mmHg (p < 0.001), and pulse pressures (PPs) from ABPM were reduced (p < 0.001). Additionally, significant reductions in night‐time SBP standard deviations (SDs) (14.7 ± 4.7 vs. 12.5 ± 3.9, p = 0.029) were observed at 12 weeks compared to baseline. OBPs significantly dropped from 151.1 ± 9.7/89.3 ± 8.3 mmHg to 125.5 ± 13.8/77.8 ± 8.8 mmHg after 12 weeks of SPC therapy (p < 0.001). Reductions in PPs of OBP and baPWVs were also observed. OLM/AML SPC therapy effectively reduced the 24‐h mean BP, as measured by ABPM, in hypertensive patients over 55 years old who failed to achieve a target SBP (< 140 mmHg) with angiotensin receptor blocker (ARB) monotherapy using valsartan 80 mg or candesartan 8 mg. Trial Registration: ClinicalTrials.gov identifier: NCT01713920 |
| Author | Chung, Woo‐Baek Choi, Yun‐Seok Ihm, Sang‐Hyun Youn, Ho‐Joong |
| AuthorAffiliation | 1 Division of Cardiology Department of Internal Medicine Seoul St. Mary's Hospital The Catholic University of Korea Seoul South Korea 3 Division of Cardiology Department of Internal Medicine Bucheon St. Mary's Hospital The Catholic University of Korea Seoul South Korea 2 The Catholic Research Institute for Intractable Cardiovascular Disease College of Medicine The Catholic University of Korea Seoul South Korea |
| AuthorAffiliation_xml | – name: 3 Division of Cardiology Department of Internal Medicine Bucheon St. Mary's Hospital The Catholic University of Korea Seoul South Korea – name: 1 Division of Cardiology Department of Internal Medicine Seoul St. Mary's Hospital The Catholic University of Korea Seoul South Korea – name: 2 The Catholic Research Institute for Intractable Cardiovascular Disease College of Medicine The Catholic University of Korea Seoul South Korea |
| Author_xml | – sequence: 1 givenname: Woo‐Baek surname: Chung fullname: Chung, Woo‐Baek organization: The Catholic University of Korea – sequence: 2 givenname: Sang‐Hyun orcidid: 0000-0001-5017-5421 surname: Ihm fullname: Ihm, Sang‐Hyun email: heartihmsh@yahoo.co.kr organization: The Catholic University of Korea – sequence: 3 givenname: Yun‐Seok surname: Choi fullname: Choi, Yun‐Seok organization: The Catholic University of Korea – sequence: 4 givenname: Ho‐Joong surname: Youn fullname: Youn, Ho‐Joong organization: The Catholic University of Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39504016$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks9u1DAQxiNURP_AgRdAlrgA0nbtxInjU7WsCi1qaUWBq-U4zq5Xjh3shCo3HoFH4ll4EmabUlEkiKzYnvnN5y8Z7yc7zjudJE8JPiTwzDdqfUgoT_mDZI-wnMwYYcUOrPOUzgqI7Cb7MW4wzrOM40fJbsZzTDEp9pIfx01jlFQj8g26sK2OMvTSzRet9bXpjNPoyriV1T-_fb801qKlbyvjZG-8QzBSCok1OtfSoasx9t4ahV5b72t0GXSMQ9Db5HauUTWiRVsNVvY-jOjcOwMLUEfGoffegdIHHTvvah0i6j36LO1kB_mAlhLit1so9f1aB9mNj5OHDWD6ye18kHx6c_xxeTI7u3h7ulyczRRlmM-yRpGc16qmVc5JnWaEEcI0r-oCZ2mpcg4pmfKGqyalVOlKVTJvKC0LVtYUZwfJ6aRbe7kRXTCtDKPw0oibgA8rAd6Mslo0rMRSQmkK7yzNJPQBDk_LEnPCSgVaryatwXVyvJbW3gkSLLYtFdBScdNSgI8muBuqVtdKuz5Ie8_B_Ywza7HyX0GHwT1gDBRe3CoE_2XQsRetiUpbK532QxQZSWnBCSYU0Od_oRs_BAc_FqiCFLjEZQHUsz8t3Xn5fa0AeDkBKvgYg27--33zib02Vo__BsW75clU8QsT1vET |
| Cites_doi | 10.1016/S0140-6736(07)61538-4 10.1590/S0066-782X2006000100007 10.1038/sj.jhh.1001577 10.1186/s40885-023-00234-9 10.3810/pgm.2011.01.2248 10.1007/s40119-017-0087-5 10.1016/j.kjms.2012.09.005 10.1016/j.ijcrp.2021.200102 10.1111/j.1524-6175.2001.01136.x 10.1177/1753944711432902 10.1186/s40885-019-0129-5 10.1161/HYPERTENSIONAHA.114.03694 10.5049/EBP.2023.21.2.45 10.1038/sj.jhh.1002119 10.1097/HJH.0000000000003480 10.1007/s12272-014-0446-x 10.1056/NEJMoa1803180 10.1186/s40885-024-00262-z 10.1177/1470320309342735 10.2165/00003495-200262030-00003 10.1038/s41371-020-0351-3 10.1111/j.1751-7176.2008.00050.x 10.1038/hr.2014.26 10.1111/j.1524-6175.2007.06395.x 10.1161/HYPERTENSIONAHA.120.15781 10.1007/s40292-020-00370-5 10.2165/00044011-200323070-00001 10.1016/j.ijcard.2017.12.026 10.1111/jch.14695 10.1016/j.amjmed.2016.08.032 |
| ContentType | Journal Article |
| Copyright | 2024 The Author(s). published by Wiley Periodicals LLC. 2024 The Author(s). The Journal of Clinical Hypertension published by Wiley Periodicals LLC. 2025. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2024 The Author(s). published by Wiley Periodicals LLC. – notice: 2024 The Author(s). The Journal of Clinical Hypertension published by Wiley Periodicals LLC. – notice: 2025. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.1111/jch.14929 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1751-7176 |
| EndPage | n/a |
| ExternalDocumentID | oai_doaj_org_article_f780aa4482aa4323a15215928809178c 10.1111/jch.14929 PMC11771777 39504016 10_1111_jch_14929 JCH14929 |
| Genre | article Multicenter Study Journal Article Clinical Trial, Phase IV |
| GroupedDBID | --- 0R~ 10A 123 1OC 24P 29K 31~ 36B 4.4 51W 51X 52M 52N 52P 52R 52S 52X 53G 5LA 5VS 7PT 7X7 8-1 8FI 8FJ 8UM A00 AAHHS AAWTL AAZKR ABUWG ACCFJ ACCMX ACXQS AEEZP AENEX AEQDE AEUQT AFBPY AFKRA AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN BENPR BFHJK CAG CCPQU COF CS3 D-I DU5 EBS EJD EMOBN ESX F5P FRJ FYUFA G-S GODZA GROUPED_DOAJ HF~ HMCUK HZ~ J0M LC2 LC3 LH4 LW6 MY~ N9A O9- OIG OK1 OVD P2P P4E PIMPY Q11 QB0 RPM RWI SUPJJ TEORI UKHRP WIN WYJ XG1 XV2 AAMMB AAYXX AEFGJ AGXDD AIDQK AIDYY CITATION PHGZM PHGZT PUEGO CGR CUY CVF ECM EIF NPM K9. 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c4709-3fc159dcd4b591d2317117e9bd60328c59cd4a29f9cf244cebcba5f448678d403 |
| IEDL.DBID | DOA |
| ISSN | 1524-6175 1751-7176 |
| IngestDate | Fri Oct 03 12:51:59 EDT 2025 Sun Oct 26 03:54:16 EDT 2025 Tue Sep 30 17:05:47 EDT 2025 Thu Oct 02 04:12:24 EDT 2025 Tue Oct 07 07:00:53 EDT 2025 Mon Jul 21 06:01:34 EDT 2025 Wed Oct 01 06:33:48 EDT 2025 Fri Jan 31 10:08:28 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | blood pressure variability ambulatory blood pressure measurement antihypertensive therapy isolated systolic hypertension hypertension |
| Language | English |
| License | Attribution-NonCommercial 2024 The Author(s). The Journal of Clinical Hypertension published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4709-3fc159dcd4b591d2317117e9bd60328c59cd4a29f9cf244cebcba5f448678d403 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-5017-5421 |
| OpenAccessLink | https://doaj.org/article/f780aa4482aa4323a15215928809178c |
| PMID | 39504016 |
| PQID | 3161608086 |
| PQPubID | 5070786 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f780aa4482aa4323a15215928809178c unpaywall_primary_10_1111_jch_14929 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11771777 proquest_miscellaneous_3124691014 proquest_journals_3161608086 pubmed_primary_39504016 crossref_primary_10_1111_jch_14929 wiley_primary_10_1111_jch_14929_JCH14929 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2025 |
| PublicationDateYYYYMMDD | 2025-01-01 |
| PublicationDate_xml | – month: 01 year: 2025 text: January 2025 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: New York – name: Hoboken |
| PublicationTitle | The journal of clinical hypertension (Greenwich, Conn.) |
| PublicationTitleAlternate | J Clin Hypertens (Greenwich) |
| PublicationYear | 2025 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 2017; 6 2013; 29 2016; 129 2024; 30 2003; 17 2008; 10 2019; 381 2014; 64 2023; 21 2021; 35 2018; 254 2023; 41 2021; 10 2023; 25 2006; 86 2009; 10 2021; 77 2007; 370 2023; 29 2002; 62 2019; 25 2014; 37 2007; 9 2020; 27 2001; 3 2012; 6 2007; 21 2011; 123 2003; 23 e_1_2_10_23_1 e_1_2_10_24_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_12_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_10_1 e_1_2_10_11_1 e_1_2_10_31_1 e_1_2_10_30_1 e_1_2_10_29_1 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_25_1 e_1_2_10_26_1 |
| References_xml | – volume: 77 start-page: 692 year: 2021 end-page: 705 article-title: Adherence to Single‐Pill Versus Free‐Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta‐Analysis publication-title: Hypertension – volume: 27 start-page: 157 year: 2020 end-page: 164 article-title: Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering From Hypertension and/or Dyslipidemia: Results of a Meta‐Analysis publication-title: High Blood Pressure & Cardiovascular Prevention – volume: 370 start-page: 1219 year: 2007 end-page: 1229 article-title: Prognostic Accuracy of Day Versus Night Ambulatory Blood Pressure: A Cohort Study publication-title: Lancet – volume: 64 start-page: 487 year: 2014 end-page: 493 article-title: Added Predictive Value of Night‐Time Blood Pressure Variability for Cardiovascular Events and Mortality: The Ambulatory Blood Pressure‐International Study publication-title: Hypertension – volume: 10 start-page: 930 year: 2008 end-page: 935 article-title: Early Antihypertensive Efficacy of Olmesartan Medoxomil publication-title: Journal of Clinical Hypertension (Greenwich, Conn) – volume: 254 start-page: 328 year: 2018 end-page: 332 article-title: Is Early and Fast Blood Pressure Control Important in Hypertension Management? publication-title: International Journal of Cardiology – volume: 41 start-page: 1874 year: 2023 end-page: 2071 article-title: 2023 ESH Guidelines for the Management of Arterial Hypertension the Task Force for the Management of Arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA) publication-title: Journal of Hypertension – volume: 23 start-page: 419 year: 2003 end-page: 430 article-title: Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil Assessed by 24‐Hour Ambulatory Blood Pressure Monitoring in Patients With Essential Hypertension publication-title: Clinical Drug Investigation – volume: 21 start-page: 45 year: 2023 end-page: 52 article-title: The Efficacy of Single‐Pill Combination of Olmesartan Medoxomil and Amlodipine Besylate on Office Blood Pressure in Hypertensive Patients Who Did Not Respond to Amlodipine Besylate Monotherapy publication-title: Electrolytes & Blood Pressure – volume: 6 start-page: 13 year: 2017 end-page: 32 article-title: Management of Hypertension Using Olmesartan Alone or in Combination publication-title: Cardiology and Therapy – volume: 17 start-page: 425 year: 2003 end-page: 432 article-title: Antihypertensive Efficacy and Safety of Olmesartan Medoxomil Compared With Amlodipine for Mild‐to‐Moderate Hypertension publication-title: Journal of Human Hypertension – volume: 6 start-page: 31 year: 2012 end-page: 44 article-title: Olmesartan/Amlodipine: Blood Pressure Lowering and Beyond in Special Populations publication-title: Therapeutic Advances in Cardiovascular Disease – volume: 35 start-page: 101 year: 2021 end-page: 103 article-title: Prevalence and Trends of Isolated Systolic Hypertension Among Untreated Older People in the US According to the 2017 ACC/AHA Guideline, 2001–16 publication-title: Journal of Human Hypertension – volume: 86 start-page: 39 year: 2006 end-page: 51 article-title: The “LOTHAR” Study: Evaluation of Efficacy and Tolerability of the Fixed Combination of Amlodipine and Losartan in the Treatment of Essential Hypertension publication-title: Arquivos Brasileiros De Cardiologia – volume: 10 year: 2021 article-title: Projecting the Long‐Term Benefits of Single Pill Combination Therapy for Patients With Hypertension in Five Countries publication-title: International Journal of Cardiology Cardiovascular Risk and Prevention – volume: 62 start-page: 443 year: 2002 end-page: 462 article-title: Rationale for Fixed‐Dose Combinations in the Treatment of Hypertension: The Cycle Repeats publication-title: Drugs – volume: 3 start-page: 283 year: 2001 end-page: 291 article-title: Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension publication-title: Journal of Clinical Hypertension (Greenwich, Conn) – volume: 21 start-page: 107 year: 2007 end-page: 113 article-title: The Prevalence and Risk Factors Associated With Isolated Untreated Systolic Hypertension in Korea: The Korean National Health and Nutrition Survey 2001 publication-title: Journal of Human Hypertension – volume: 37 start-page: 836 year: 2014 end-page: 844 article-title: Efficacy of Olmesartan/Amlodipine Combination Therapy in Reducing Ambulatory Blood Pressure in Moderate‐to‐Severe Hypertensive Patients Not Controlled by Amlodipine Alone publication-title: Hypertension Research – volume: 10 start-page: 147 year: 2009 end-page: 156 article-title: Efficacy in Angiotensin Receptor Blockade: A Comparative Review of Data With Olmesartan publication-title: Journal of the Renin‐Angiotensin‐Aldosterone System – volume: 29 start-page: 265 year: 2013 end-page: 270 article-title: Efficacy and Tolerability Between an Olmesartan/Amlodipine Fixed‐Dose Combination and an Amlodipine Double Dose in Mild to Moderate Hypertension publication-title: The Kaohsiung Journal of Medical Sciences – volume: 9 start-page: 187 year: 2007 end-page: 195 article-title: Comparison of Increasing Doses of Olmesartan Medoxomil, Losartan Potassium, and Valsartan in Patients With Essential Hypertension publication-title: Journal of Clinical Hypertension (Greenwich, Conn) – volume: 123 start-page: 80 year: 2011 end-page: 87 article-title: A Randomized, Double‐Blind, Forced‐Titration Study to Compare Olmesartan Medoxomil Versus Losartan Potassium in Patients With Stage 1 and 2 Hypertension publication-title: Postgraduate Medicine – volume: 129 start-page: 1251 year: 2016 end-page: 1258 article-title: Isolated Systolic Hypertension: An Update After Sprint publication-title: American Journal of Medicine – volume: 30 start-page: 7 year: 2024 article-title: Korea Hypertension Fact Sheet 2023: Analysis of Nationwide Population‐Based Data With a Particular Focus on Hypertension in Special Populations publication-title: Clinical Hypertension – volume: 29 start-page: 11 year: 2023 article-title: The 2022 Focused Update of the 2018 Korean Hypertension Society Guidelines for the Management of Hypertension publication-title: Clinical Hypertension – volume: 25 start-page: 661 year: 2023 end-page: 688 article-title: Angiotensin‐Converting Enzyme Inhibitor Induced Cough Compared With Placebo, and Other Antihypertensives: A Systematic Review, and Network Meta‐Analysis publication-title: Journal of Clinical Hypertension (Greenwich, Conn) – volume: 25 start-page: 26 year: 2019 article-title: Differences in Prevalence of Hypertension Subtypes According to the 2018 Korean Society of Hypertension and 2017 American College of Cardiology/American Heart Association Guidelines: The Korean National Health and Nutrition Examination Survey, 2007–2017 (KNHANES IV‐VII) publication-title: Clinical Hypertension – volume: 37 start-page: 1588 year: 2014 end-page: 1598 article-title: Efficacy and Safety of Olmesartan Medoxomil/Amlodipine Fixed‐Dose Combination for Hypertensive Patients Uncontrolled With Monotherapy publication-title: Archives of Pharmacal Research – volume: 381 start-page: 243 year: 2019 end-page: 251 article-title: Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes publication-title: New England Journal of Medicine – ident: e_1_2_10_8_1 doi: 10.1016/S0140-6736(07)61538-4 – ident: e_1_2_10_13_1 doi: 10.1590/S0066-782X2006000100007 – ident: e_1_2_10_12_1 doi: 10.1038/sj.jhh.1001577 – ident: e_1_2_10_7_1 doi: 10.1186/s40885-023-00234-9 – ident: e_1_2_10_27_1 doi: 10.3810/pgm.2011.01.2248 – ident: e_1_2_10_10_1 doi: 10.1007/s40119-017-0087-5 – ident: e_1_2_10_15_1 doi: 10.1016/j.kjms.2012.09.005 – ident: e_1_2_10_31_1 doi: 10.1016/j.ijcrp.2021.200102 – ident: e_1_2_10_26_1 doi: 10.1111/j.1524-6175.2001.01136.x – ident: e_1_2_10_9_1 doi: 10.1177/1753944711432902 – ident: e_1_2_10_18_1 doi: 10.1186/s40885-019-0129-5 – ident: e_1_2_10_22_1 doi: 10.1161/HYPERTENSIONAHA.114.03694 – ident: e_1_2_10_14_1 doi: 10.5049/EBP.2023.21.2.45 – ident: e_1_2_10_6_1 doi: 10.1038/sj.jhh.1002119 – ident: e_1_2_10_4_1 doi: 10.1097/HJH.0000000000003480 – ident: e_1_2_10_16_1 doi: 10.1007/s12272-014-0446-x – ident: e_1_2_10_21_1 doi: 10.1056/NEJMoa1803180 – ident: e_1_2_10_2_1 doi: 10.1186/s40885-024-00262-z – ident: e_1_2_10_28_1 doi: 10.1177/1470320309342735 – ident: e_1_2_10_3_1 doi: 10.2165/00003495-200262030-00003 – ident: e_1_2_10_19_1 doi: 10.1038/s41371-020-0351-3 – ident: e_1_2_10_29_1 doi: 10.1111/j.1751-7176.2008.00050.x – ident: e_1_2_10_17_1 doi: 10.1038/hr.2014.26 – ident: e_1_2_10_25_1 doi: 10.1111/j.1524-6175.2007.06395.x – ident: e_1_2_10_11_1 doi: 10.1161/HYPERTENSIONAHA.120.15781 – ident: e_1_2_10_30_1 doi: 10.1007/s40292-020-00370-5 – ident: e_1_2_10_24_1 doi: 10.2165/00044011-200323070-00001 – ident: e_1_2_10_23_1 doi: 10.1016/j.ijcard.2017.12.026 – ident: e_1_2_10_5_1 doi: 10.1111/jch.14695 – ident: e_1_2_10_20_1 doi: 10.1016/j.amjmed.2016.08.032 |
| SSID | ssj0053390 |
| Score | 2.388464 |
| Snippet | ABSTRACT
The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single‐pill combination (SPC) therapy using ambulatory blood... The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single‐pill combination (SPC) therapy using ambulatory blood pressure... The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single-pill combination (SPC) therapy using ambulatory blood pressure... ABSTRACT The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single‐pill combination (SPC) therapy using ambulatory blood... |
| SourceID | doaj unpaywall pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | e14929 |
| SubjectTerms | Aged ambulatory blood pressure measurement Amlodipine - administration & dosage Amlodipine - therapeutic use Antihypertensive Agents - administration & dosage Antihypertensive Agents - therapeutic use antihypertensive therapy Benzimidazoles - administration & dosage Benzimidazoles - therapeutic use Biphenyl Compounds Blood pressure Blood Pressure - drug effects Blood Pressure Monitoring, Ambulatory - methods blood pressure variability Drug Combinations Female Humans Hypertension Hypertension - drug therapy Hypertension - physiopathology Imidazoles - administration & dosage Imidazoles - therapeutic use isolated systolic hypertension Male Middle Aged Original Pulse Wave Analysis Tetrazoles - administration & dosage Tetrazoles - therapeutic use Treatment Outcome Valsartan |
| SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dbtMwFLZGJwE3_MMCA3nABTfd6sRO4suu2lRNapmAonEVOY6tVmTJ1LVC4YpH4JF4Fp6Ec5w0EH4mpKhN6x858TnHn-1zPhPykgvOWMZAkUIt-lwChoNxHdRd2IExSsEoi-uQk2k4nvGTM3G2RfY2sTC_7t87jxvobADxvrxGtkMBcLtHtmfT0-EHx4PqcwxxEy7oUbA-TE3Chj2oU7Yz5jhq_r_hyT_dIm-siwtVfVJ53oWubuw5vv0zgqd2Ofm4v16l-_rzb4SOVz7WHXKrQZ50WIvKXbJlinvk-qTZW79Pvh0hm4TSFS0tfY2BCiBVqjgYnudlhidcG_oWxrncfP_y9XSR5xRMCUyrXc9SuHwOCXM6MaqgyIOOhMP0EP3iaR2DuDSYiN8ZTSs6PE_x6LByWdHasOAKI10UdFoWUNMb57yLbtZ0VdL3oCWuObRc0hEufDc_oWgTQ1Y9ILPjo3ejcb8536GveYQuF1YDmMp0xlMhWQZIM2IsMjLNQmT500JCkvKlldoCCtEm1akSliNJYJzxQfCQ9IqyMDuExkEAOEbZDGtj1sYmttFAp5qFyjdceeT5RgKSi5rGI2mnP3qeuL7wyCHKRpsBmbfdH9BzSaPIiY3igVLQBh8-Az9QCICE9MEOwsw31h7Z3UhW0piDyyQAXB0CNo9Dj-y1yaDIuDujClOuMY_PQ4lHJ3vkUS2IbUsCKcDYMigdd0S009RuSrGYO7Jw3JSHK_LIi1aar3oFr5yc_ztHcjIau5vH_1XhE3LTxxOT3aLVLumtlmvzFGDcKn3WKPIPukRHfA priority: 102 providerName: Unpaywall – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bi9QwFA7rCuqLeLe6Srw8-DI4aZO2wafZYZdhYdZFXdm3kqbJzkA3XbozSN_8Cf4kf4u_xHPSCxYvCKVzSVJCcy5fTk6-EPKaC85YwUCRYi0mXAKGA78O6i7s1BilwMtiHHJ5HC9O-dGZONsh7_q9MC0_xBBwQ83w9hoVXOVXvyo5iAHA-1BeI9cZ4BgU75Cf9GYYYIwPsIB_4rgPTnS0Qj6Np286ckaes_9PQPP3fMmbW3epmi-qLMeY1julwzvkdocm6awd_rtkx7h75MayWy-_T74fIEOE0g2tLH2Pmw9AUpR7O7soqwJPrTb0I_iu0vz4-u1kXZYUzANMlf1oUbhCDgUrujTKUeQ2RxJhuo-57rTdV1gbLMTPguYNnV3keBxYVTe0NRYYNaRrR48rB0_64BNyMXWabir6GSTfd4dWNZ1jMLv7CU27fWHNA3J6ePBpvph0ZzZMNE8wjcJqAEiFLnguJCsAPSaMJUbmRYzMfVpIKFKhtFJbQBba5DpXwnIk_ksLPo0ekl1XOfOY0DSKAJsoW-DTmLWpSW0y1blmsQoNVwF52Q9edtlSc2TDlEavMj_CAdnHYR0qIJu2_6Oqz7NOOTObpFOloA8h3KMwUghqhAzBtsFsNtUB2euFIutU_CqLACvHgLfTOCAvhmJQTlxxUc5UW6wT8ljiccgBedTK0NCTSAowoAxapyPpGnV1XOLWK08AjgvtcCUBeTUI4r9ewRsvon-vkR3NF_7Lk_-v-pTcCvEoZB-N2iO7m3prngE-2-TPvR7-BM1MOu8 priority: 102 providerName: Wiley-Blackwell |
| Title | Efficacy of Olmesartan/Amlodipine Single‐Pill Combination on 24‐h Mean Systolic Blood Pressure Measured by Ambulatory Monitoring in Non‐Responders to Valsartan or Candesartan Monotherapy |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjch.14929 https://www.ncbi.nlm.nih.gov/pubmed/39504016 https://www.proquest.com/docview/3161608086 https://www.proquest.com/docview/3124691014 https://pubmed.ncbi.nlm.nih.gov/PMC11771777 https://doi.org/10.1111/jch.14929 https://doaj.org/article/f780aa4482aa4323a15215928809178c |
| UnpaywallVersion | publishedVersion |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals (DOAJ) customDbUrl: eissn: 1751-7176 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053390 issn: 1751-7176 databaseCode: DOA dateStart: 20210101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1751-7176 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053390 issn: 1751-7176 databaseCode: RPM dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1751-7176 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053390 issn: 1751-7176 databaseCode: 7X7 dateStart: 20210401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1751-7176 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053390 issn: 1751-7176 databaseCode: BENPR dateStart: 20210401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 1751-7176 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0053390 issn: 1751-7176 databaseCode: 24P dateStart: 20210101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgkYAL4rkElso8DlyqzcNO4mNbdVWt1FItFJVT5Di2WinrrEorlBs_gZ_Eb-GXMOOkgYrXBSlKk9qJHHvs-cYef0PIK8ZZEBQBdKRY8T4TgOFAr0N358bXWkrQsjgPOZ3FkwU7X_LlT6G-0CesoQduKu7UJKkvJRgRIZyjMJKocLgIQe7A0kgVjr5-KvbGVDMGA4ZxsyuQl-EmON5yCjkfHhAfMAscpvyhiRxh_-9Q5q_Okrd29krWn2RZHgJap5HO7pI7LZSkg-YT7pFr2t4nN6ftYvkD8nWM9BBS1bQy9A3uPICvlfZ0cFlWBYas1vQtKK5Sf_v8Zb4uSwpjA9jJrqkoHCGDhBWdamkpEpsjgzAdoqM7bTYVbjQm4m9B85oOLnOMBVZtatqMFDhlSNeWzioLb7pw3rjoN023FX0PYu-KQ6sNHeFMdnsLj7abwuqHZHE2fjea9NuADX3FEvShMAqaplAFy7kICoCOSRAkWuRFjLR9igtIkqEwQhmAFUrnKpfcMGT9SwvmR4_Ika2sfkxoGkUATKQp8G2BMalOTeKrXAWxDDWTHnmxb7zsquHlyDp7Rq0y18IeGWKzdhmQStv9AQKWtQKW_UvAPHKyF4qs7d8fswiAcgxgO4098rxLhp6Jyy3S6mqHeUIWC4yF7JHjRoa6kkSCw-gZwNPpgXQdFPUwxa5Xjv0bV9nhSDzyshPEv1XBayeif86RnY8m7uLJ_6itp-R2iBGS3STVCTnabnb6GcC2bd4j10M2h3OyTHrkxnA8m1_0XK-Fu8VsPvjwHYqwRqU |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3ZbtQwFLVKkSgviJ1AAbM88DLqxLGzSLxMR62G0hkqaFHfIsexmZFSpwozQnnjE_gkvoUv4V5nERGLkKLMYjuy4rscX18fE_KSC-77uQ-KFCox4glgOPDroO7CjLWWErwsxiHni3B2xo_OxfkWed3thWn4IfqAG2qGs9eo4BiQ_lXLQQ4A37PkCrnKQz_EqRfjJ50dBhzjIizgoDhuhBMtr5DL4-maDryRI-3_E9L8PWFyZ2MvZf1FFsUQ1DqvdHiT3GjhJJ0043-LbGl7m1ybtwvmd8j3A6SIkKqmpaHvcPcBiIq0e5OLoszx2GpNP4DzKvSPr99OVkVBwT7AXNkNF4WLcShY0rmWliK5ObII031MdqfNxsJKYyF-5jSr6eQiw_PAyqqmjbXAsCFdWbooLTzpvcvIxdxpui7pRxB91x1aVnSK0ez2JzRtN4bVd8nZ4cHpdDZqD20YKR5hHoVRgJBylfNMJH4O8DHy_UgnWR4idZ8SCRRJlphEGYAWSmcqk8JwZP6Lcz4O7pFtW1r9gNA4CACcSJPj03xjYh2baKwy5YeSaS498rwbvPSy4eZI-zmNWqZuhD2yj8PaV0A6bfdHWX1KW-1MTRSPpYQ-MLgHLJCIakTCwLjBdDZWHtnthCJtdfxzGgBYDgFwx6FHnvXFoJ245CKtLjdYh_EwwfOQPXK_kaG-J0EiwIL60DoeSNegq8MSu1o6BnBcaYcr8siLXhD_9QpeORH9e430aDpzXx7-f9WnZGd2Oj9Oj98s3j4i1xmei-xCU7tke11t9GMAa-vsidPJn7EoPls |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3ZjtMwFLWGQRp4QewEBjDLAy8VTWInscRLp0xVBloqYNC8RY4XWimTVKEVyhufwCfxLXwJ9zqLqFiEFKWL7ciK73J8fX1MyFPGme9rHxQpUnzABGA48Oug7twOjZESvCzGIWfzaHrKTs742R550e2Fafgh-oAbaoaz16jgZq3tr1oOcgD4PhAXyEXGwRMirzNbdHYYcIyLsICDYrgRjre8Qi6Pp2u6440caf-fkObvCZOXtsVa1l9knu-CWueVJlfJlRZO0lEz_tfInimuk4NZu2B-g3w_RooIqWpaWvoWdx-AqMji-eg8LzUeW23oe3Beufnx9dtilecU7APMld1wUbgCBgVLOjOyoEhujizC9AiT3WmzsbAyWIifmmY1HZ1neB5YWdW0sRYYNqSrgs7LAp70zmXkYu403ZT0I4i-6w4tKzrGaHb7E5q2G8Pqm-R0cvxhPB20hzYMFIsxj8IqQEhaaZZx4WuAj7Hvx0ZkOkLqPsUFFMlAWKEsQAtlMpVJbhky_yWaDcNbZL8oC3OH0CQMAZxIq_FpvrWJSWw8VJnyIxkYJj3yuBu8dN1wc6T9nEYtUzfCHjnCYe0rIJ22-6OsPqWtdqY2ToZSQh8CuIdBKBHVcBGAcYPpbKI8ctgJRdrq-Oc0BLAcAeBOIo886otBO3HJRRam3GKdgEUCz0P2yO1GhvqehIKDBfWhdbIjXTtd3S0pVkvHAI4r7XDFHnnSC-K_XsEzJ6J_r5GejKfuy93_r_qQHCxeTtI3r-av75HLAR6L7CJTh2R_U23NfcBqm-yBU8mfH0c96g |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dbtMwFLZGJwE3_MMCA3nABTfd6sRO4suu2lRNapmAonEVOY6tVmTJ1LVC4YpH4JF4Fp6Ec5w0EH4mpKhN6x858TnHn-1zPhPykgvOWMZAkUIt-lwChoNxHdRd2IExSsEoi-uQk2k4nvGTM3G2RfY2sTC_7t87jxvobADxvrxGtkMBcLtHtmfT0-EHx4PqcwxxEy7oUbA-TE3Chj2oU7Yz5jhq_r_hyT_dIm-siwtVfVJ53oWubuw5vv0zgqd2Ofm4v16l-_rzb4SOVz7WHXKrQZ50WIvKXbJlinvk-qTZW79Pvh0hm4TSFS0tfY2BCiBVqjgYnudlhidcG_oWxrncfP_y9XSR5xRMCUyrXc9SuHwOCXM6MaqgyIOOhMP0EP3iaR2DuDSYiN8ZTSs6PE_x6LByWdHasOAKI10UdFoWUNMb57yLbtZ0VdL3oCWuObRc0hEufDc_oWgTQ1Y9ILPjo3ejcb8536GveYQuF1YDmMp0xlMhWQZIM2IsMjLNQmT500JCkvKlldoCCtEm1akSliNJYJzxQfCQ9IqyMDuExkEAOEbZDGtj1sYmttFAp5qFyjdceeT5RgKSi5rGI2mnP3qeuL7wyCHKRpsBmbfdH9BzSaPIiY3igVLQBh8-Az9QCICE9MEOwsw31h7Z3UhW0piDyyQAXB0CNo9Dj-y1yaDIuDujClOuMY_PQ4lHJ3vkUS2IbUsCKcDYMigdd0S009RuSrGYO7Jw3JSHK_LIi1aar3oFr5yc_ztHcjIau5vH_1XhE3LTxxOT3aLVLumtlmvzFGDcKn3WKPIPukRHfA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+Olmesartan%2FAmlodipine+Single%E2%80%90Pill+Combination+on+24%E2%80%90h+Mean+Systolic+Blood+Pressure+Measured+by+Ambulatory+Monitoring+in+Non%E2%80%90Responders+to+Valsartan+or+Candesartan+Monotherapy&rft.jtitle=The+journal+of+clinical+hypertension+%28Greenwich%2C+Conn.%29&rft.au=Woo%E2%80%90Baek+Chung&rft.au=Sang%E2%80%90Hyun+Ihm&rft.au=Yun%E2%80%90Seok+Choi&rft.au=Ho%E2%80%90Joong+Youn&rft.date=2025-01-01&rft.pub=Wiley&rft.issn=1524-6175&rft.eissn=1751-7176&rft.volume=27&rft.issue=1&rft.epage=n%2Fa&rft_id=info:doi/10.1111%2Fjch.14929&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_f780aa4482aa4323a15215928809178c |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1524-6175&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1524-6175&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1524-6175&client=summon |